Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | COM503: the next steps in harnessing cytokines to treat cancer

Eran Ophir • 30 May 2023
General COM503

Eran Ophir, PhD, Compugen Ltd., Tel Aviv, Israel, discusses future research directions for COM503, a potential first-in-class, high affinity anti- IL18 binding protein antibody with a novel approach to harnessing cytokine biology to treat cancer, including identifying suitable indications and biomarkers for this therapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Eran Ophir

0:59
COM503: harnessing cytokine biology to treat cancer
Eran Ophir • 30 May 2023
3:19
Targeting IL18 with COM503 to treat cancer
Eran Ophir • 30 May 2023
2:28
Targeting cold tumors with anti-PVRIG immunotherapy
Eran Ophir • 26 Oct 2022

Related Videos

2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals